Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

[Simulation of bioequivalence study on the base of dissolution curves].

Grezál G, Vereczkey L.

Acta Pharm Hung. 2012;82(2):55-9. Hungarian.

PMID:
22870777
2.

Differential inhibitory effect of cyclosporin A and bosentan on taurocholate uptake in human and rat hepatocytes as a function of culturing time.

Jemnitz K, Veres Z, Szabo M, Baranyai Z, Jakab F, Vereczkey L.

Toxicol In Vitro. 2012 Feb;26(1):174-81. doi: 10.1016/j.tiv.2011.11.005. Epub 2011 Nov 18.

PMID:
22119333
3.

Transporter-drug interactions and transporter-mediated toxicity in the liver/hepatocyte. Preface.

Krajcsi P, Vereczkey L.

Drug Metab Rev. 2010 Aug;42(3):379. doi: 10.3109/03602530903492129. No abstract available.

PMID:
20597844
4.

Contribution of high basolateral bile salt efflux to the lack of hepatotoxicity in rat in response to drugs inducing cholestasis in human.

Jemnitz K, Veres Z, Vereczkey L.

Toxicol Sci. 2010 May;115(1):80-8. doi: 10.1093/toxsci/kfq044. Epub 2010 Feb 10.

PMID:
20147439
5.

ABCC2/Abcc2: a multispecific transporter with dominant excretory functions.

Jemnitz K, Heredi-Szabo K, Janossy J, Ioja E, Vereczkey L, Krajcsi P.

Drug Metab Rev. 2010 Aug;42(3):402-36. doi: 10.3109/03602530903491741. Review.

PMID:
20082599
6.

Potentiation of MRP2/Mrp2-mediated estradiol-17beta-glucuronide transport by drugs--a concise review.

Herédi-Szabó K, Jemnitz K, Kis E, Ioja E, Jánossy J, Vereczkey L, Krajcsi P.

Chem Biodivers. 2009 Nov;6(11):1970-4. doi: 10.1002/cbdv.200900102. Review. No abstract available.

PMID:
19937833
7.

Biliary efflux transporters involved in the clearance of rosuvastatin in sandwich culture of primary rat hepatocytes.

Jemnitz K, Veres Z, Tugyi R, Vereczkey L.

Toxicol In Vitro. 2010 Mar;24(2):605-10. doi: 10.1016/j.tiv.2009.10.009. Epub 2009 Oct 21.

PMID:
19853032
8.

Limited applicability of 7-methoxy-4-trifluoromethylcoumarin as a CYP2C9-selective substrate.

Porrogi P, Kóbori L, Kõhalmy K, Gulyás J, Vereczkey L, Monostory K.

Pharmacol Rep. 2008 Nov-Dec;60(6):972-9.

9.

Interspecies differences in acetaminophen sensitivity of human, rat, and mouse primary hepatocytes.

Jemnitz K, Veres Z, Monostory K, Kóbori L, Vereczkey L.

Toxicol In Vitro. 2008 Jun;22(4):961-7. doi: 10.1016/j.tiv.2008.02.001. Epub 2008 Feb 13.

PMID:
18346862
10.

Modulation of sinusoidal and canalicular elimination of bilirubin-glucuronides by rifampicin and other cholestatic drugs in a sandwich culture of rat hepatocytes.

Lengyel G, Veres Z, Tugyi R, Vereczkey L, Molnár T, Glavinas H, Krajcsi P, Jemnitz K.

Hepatol Res. 2008 Mar;38(3):300-9. Epub 2007 Aug 29.

PMID:
17760873
11.

Effect of mirtazapine on the CYP2D activity in the primary culture of rat hepatocytes.

Haduch A, Bromek E, Kot M, Jemnitz K, Veres Z, Vereczkey L, Daniel WA.

Pharmacol Rep. 2006 Nov-Dec;58(6):979-84.

12.

Biotransformation of deramciclane in primary hepatocytes of rat, mouse, rabbit, dog, and human.

Monostory K, Kohalmy K, Ludányi K, Czira G, Holly S, Vereczkey L, Urmös I, Klebovich I, Kóbori L.

Drug Metab Dispos. 2005 Nov;33(11):1708-16. Epub 2005 Aug 23.

PMID:
16118331
13.

The spectrum of enzymes involved in activation of 2-aminoanthracene varies with the metabolic system applied.

Veres Z, Török G, Tóth E, Vereczkey L, Jemnitz K.

Mutat Res. 2005 Sep 5;586(1):18-27.

PMID:
16006184
14.

[The role of drug metabolizing enzymes in the effect and side-effect of the drugs].

Vereczkey L, Jemnitz K, Monostory K, Veres Z, Kóbori L.

Orv Hetil. 2005 May 8;146(19):947-52. Review. Hungarian.

PMID:
15969306
15.

Canalicular and sinusoidal disposition of bilirubin mono- and diglucuronides in sandwich-cultured human and rat primary hepatocytes.

Lengyel G, Veres Z, Szabó P, Vereczkey L, Jemnitz K.

Drug Metab Dispos. 2005 Sep;33(9):1355-60. Epub 2005 Jun 10.

PMID:
15951449
16.

Role of CYP2E1 in deramciclane metabolism.

Monostory K, Köhalmy K, Hazai E, Vereczkey L, Kóbori L.

Drug Metab Dispos. 2005 Nov;33(11):1717-22. Epub 2005 Jun 2.

PMID:
15932955
17.

The effect of synthetic glucocorticoid, dexamethasone on CYP1A1 inducibility in adult rat and human hepatocytes.

Monostory K, Kohalmy K, Prough RA, Kóbori L, Vereczkey L.

FEBS Lett. 2005 Jan 3;579(1):229-35.

18.

Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors.

Monostory K, Hazai E, Vereczkey L.

Chem Biol Interact. 2004 Apr 15;147(3):331-40.

PMID:
15135088
20.

In vitro induction of cytochrome P450 enzymes in hepatocytes isolated from the regenerating rat liver.

Tamási V, Riedl Z, Dobozy O, Falus A, Vereczkey L, Monostory K.

Pol J Pharmacol. 2004 Jan-Feb;56(1):113-9.

21.

GYKI-47261, a new AMPA [2-amino-3-(3-hydroxymethylisoxazole-4-yl)propionic acid] antagonist, is a CYP2E1 inducer.

Tamási V, Hazai E, Porsmyr-Palmertz M, Ingelman-Sundberg M, Vereczkey L, Monostory K.

Drug Metab Dispos. 2003 Nov;31(11):1310-4.

PMID:
14570761
22.

Some aspects of interindividual variations in the metabolism of xenobiotics.

Tamási V, Vereczkey L, Falus A, Monostory K.

Inflamm Res. 2003 Aug;52(8):322-33. Review.

PMID:
14504670
23.
25.

In vitro-in vivo correlation of the pharmacokinetics of vinpocetine.

Szakács T, Veres Z, Vereczkey L.

Pol J Pharmacol. 2001 Nov-Dec;53(6):623-8.

26.

Reduction of toxic metabolite formation of acetaminophen.

Hazai E, Vereczkey L, Monostory K.

Biochem Biophys Res Commun. 2002 Mar 8;291(4):1089-94.

PMID:
11866476
27.

In vitro induction of bilirubin conjugation in primary rat hepatocyte culture.

Jemnitz K, Lengyel G, Vereczkey L.

Biochem Biophys Res Commun. 2002 Feb 15;291(1):29-33.

PMID:
11829457
28.
29.

The effect of dexamethasone on P450 activities in regenerating rat liver.

Tamási V, Kiss A, Dobozy O, Falus A, Vereczkey L, Monostory K.

Biochem Biophys Res Commun. 2001 Aug 17;286(2):239-42.

PMID:
11500027
30.

Effect of alpha-methyldopa on pentoxyresorufin O-dealkylation in liver microsomes from rats treated with phenobarbital.

Veres Z, Szakács T, Vereczkey L.

Arch Biochem Biophys. 2001 Aug 1;392(1):59-64.

PMID:
11469794
31.

The in vitro biosynthesis and stability measurement with agyl-glycuronide isoformes of the main metabolite of ipriflavone.

Jemnitz K, Lévai F, Monostory K, Szatmári I, Vereczkey L.

Eur J Drug Metab Pharmacokinet. 2000 Jul-Dec;25(3-4):153-60.

PMID:
11420883
32.

[About paracetamol again].

Hazai E, Monostory K, Bakos A, Zacher G, Vereczkey L.

Orv Hetil. 2001 Feb 18;142(7):345-9. Review. Hungarian.

PMID:
11243017
33.

Predicting the time needed to achieve steady state if absorption and elimination constants are equal.

Singer J, Vereczkey L.

J Pharmacokinet Biopharm. 1999 Jun;27(3):297-300.

PMID:
10728491
35.

[Human drug metabolizing enzymes III. Epoxide hydrolases, esterases, and amidases].

Hazai E, Róna K, Vereczkey L.

Acta Pharm Hung. 1999 Sep;69(4):208-12. Review. Hungarian.

PMID:
10544521
36.

[Human drug metabolizing enzymes. II. Conjugation enzymes].

Vereczkey L, Jemnitz K, Gregus Z.

Acta Pharm Hung. 1998 Sep;68(5):284-8. Review. Hungarian.

PMID:
9805814
37.

[Human drug metabolizing enzymes. I. Oxidative enzymes].

Vereczkey L, Monostory K, Veres Z.

Acta Pharm Hung. 1998 Sep;68(5):276-83. Review. Hungarian.

PMID:
9805813
38.

[Mass spectrometry in the verification of pyrimethamine poisoning].

Vereczkey L, Klátyilc M, Bárdosi Z, Jemnitz K, Vékey K.

Orv Hetil. 1998 Jul 5;139(27):1639-42. Hungarian.

PMID:
9685804
39.

Ipriflavone as an inhibitor of human cytochrome P450 enzymes.

Monostory K, Vereczkey L, Lévai F, Szatmári I.

Br J Pharmacol. 1998 Feb;123(4):605-10.

40.

Species differences in metabolism of panomifene, an analogue of tamoxifen.

Monostory K, Jemnitz K, Vereczkey L, Czira G.

Drug Metab Dispos. 1997 Dec;25(12):1370-8.

PMID:
9394026
41.

Recent studies on the effects of tiamulin and monensin on hepatic cytochrome P450 activities in chickens and turkeys.

Rátz V, Laczay P, Móra Z, Csikó G, Monostori K, Vereczkey L, Lehel J, Semjén G.

J Vet Pharmacol Ther. 1997 Oct;20(5):415-8. No abstract available.

PMID:
9350266
42.

[Validation of gas and liquid chromatographic methods in the bioanalytical laboratory].

Róna K, Ary K, Vereczkey L.

Acta Pharm Hung. 1997 Mar-May;67(2-3):51-7. Hungarian.

PMID:
9289936
43.

[Some thoughts on Bateman's equation].

Vereczkey L, Singer J.

Acta Pharm Hung. 1997 Mar-May;67(2-3):43-9. Hungarian.

PMID:
9289935
44.

Human liver cytochrome P-450 and conjugating enzymes. Hungarian data.

Vereczkey L, Jemnitz K, Monostory K.

Acta Physiol Hung. 1997-1998;85(2):149-52.

PMID:
9706309
45.
46.

Xenobiotic metabolizing enzymes in fish: diversity, regulation and biomarkers for pollutant exposure.

Monostory K, Jemnitz K, Vereczkey L.

Acta Physiol Hung. 1996;84(4):369-81. Review.

PMID:
9328609
47.

The effect of ipriflavone and its main metabolites on theophylline biotransformation.

Monostory K, Vereczkey L.

Eur J Drug Metab Pharmacokinet. 1996 Jan-Mar;21(1):61-6.

PMID:
8839679
48.

[Role of human cytochrome P-450 enzymes in the metabolism of xenobiotics].

Monostory K, Vereczkey L.

Acta Pharm Hung. 1995 Sep;65(5):147-56. Review. Hungarian.

PMID:
7484161
49.

[Pharmacokinetic and metabolic studies in the development of drugs].

Vereczkey L.

Acta Pharm Hung. 1995 Jul;65(4):105-11. Hungarian.

PMID:
7572191
50.

Structure activity relationship in toxicology.

Vereczkey L.

Acta Physiol Hung. 1995;83(1):47-50.

PMID:
7660836

Supplemental Content

Loading ...
Support Center